In 2022, Cell Technology merged with ImmunoChemistry Technologies and Antibodies Inc to advance its mission of developing unique, cell-permeable assays for studying cellular functions.
Founded in 1998 and specializing in in situ detection of tissue-specific events while preserving cell morphology and architecture, Cell Technology’s trusted products, including its first line detecting apoptotic cells via active caspases and mitochondrial membrane potential loss, have empowered researchers in academia, biotechnology, and pharmaceuticals.
This merger enhances our capacity to deliver innovative reagents. Cell Technology's products remain unchanged in quality and performance, ensuring researchers can rely on consistent results. We are dedicated to enhancing your research experience, and their extensive range of dependable products perfectly complements ImmunoChemistry and Antibodies Inc's robust portfolio of cell viability assays and services.
Contact us if you have any questions!